SARS-CoV-2 nucleocapsid protein triggers hyperinflammation via protein-protein interaction-mediated intracellular Cl− accumulation in respiratory epithelium
Lei Chen, Wei‐jie Guan, Zhuo-Er Qiu, Jian-Bang Xu, Xu Bai, Xiao-Chun Hou, Jing Sun, Su Qu, Ze-Xin Huang, Tian-Lun Lei, Ziyang Huang, Jincun Zhao, Yunxin Zhu, YE Ke-nan, Zhao‐Rong Lun, Wen‐Liang Zhou, Nanshan Zhong, Yilin Zhang
Abstract
Abstract SARS-CoV-2, the culprit pathogen of COVID-19, elicits prominent immune responses and cytokine storms. Intracellular Cl − is a crucial regulator of host defense, whereas the role of Cl − signaling pathway in modulating pulmonary inflammation associated with SARS-CoV-2 infection remains unclear. By using human respiratory epithelial cell lines, primary cultured human airway epithelial cells, and murine models of viral structural protein stimulation and SARS-CoV-2 direct challenge, we demonstrated that SARS-CoV-2 nucleocapsid (N) protein could interact with Smad3, which downregulated cystic fibrosis transmembrane conductance regulator (CFTR) expression via microRNA-145. The intracellular Cl − concentration ([Cl − ] i ) was raised, resulting in phosphorylation of serum glucocorticoid regulated kinase 1 (SGK1) and robust inflammatory responses. Inhibition or knockout of SGK1 abrogated the N protein-elicited airway inflammation. Moreover, N protein promoted a sustained elevation of [Cl − ] i by depleting intracellular cAMP via upregulation of phosphodiesterase 4 (PDE4). Rolipram, a selective PDE4 inhibitor, countered airway inflammation by reducing [Cl − ] i . Our findings suggested that Cl − acted as the crucial pathological second messenger mediating the inflammatory responses after SARS-CoV-2 infection. Targeting the Cl − signaling pathway might be a novel therapeutic strategy for COVID-19.